Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events

被引：4
|
作者：
Reid, Pankti [1 ]
Sparks, Jeffrey A. [2 ]
Bass, Anne R. [3 ,4 ]
机构：
[1] Univ Chicago, Med Ctr, Div Rheumatol, Chicago, IL USA
[2] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA USA
[3] Hosp Special Surg, Div Rheumatol, Weill Cornell Med, New York, NY USA
[4] Hosp Special Surg, Weill Cornell Med, 535 E 70th St, New York, NY 10021 USA
来源：
JAMA ONCOLOGY | 2023年 / 9卷 / 05期
关键词：
D O I：
10.1001/jamaoncol.2023.0100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：723 / 724
页数：2
相关论文
共 50 条
  • [21] Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
    Silverstein, Jordyn
    Wright, Francis
    Wang, Michelle
    Young, Arabella
    Kim, Daniel
    De Dios, Kimberly
    Brondfield, Sam
    Quandt, Zoe
    ONCOLOGIST, 2023, 28 (10): : e950 - e959
  • [22] Guarantee-time bias in studies on the relationship between immune-related adverse events and antitumor activity
    Cheung, Ka Man
    Tsui, Therese Yue Man
    Chow, James Chung Hang
    CANCER, 2022, 128 (13) : 2549 - 2550
  • [23] Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes
    Matsukane, Ryosuke
    Suetsugu, Kimitaka
    Hata, Kojiro
    Matsuda, Keisuke
    Nakao, Satoshi
    Minami, Haruna
    Watanabe, Hiroyuki
    Hirota, Takeshi
    Egashira, Nobuaki
    Ieiri, Ichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (07) : 860 - 871
  • [24] Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes
    Ryosuke Matsukane
    Kimitaka Suetsugu
    Kojiro Hata
    Keisuke Matsuda
    Satoshi Nakao
    Haruna Minami
    Hiroyuki Watanabe
    Takeshi Hirota
    Nobuaki Egashira
    Ichiro Ieiri
    International Journal of Clinical Oncology, 2023, 28 : 860 - 871
  • [25] Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events Reply
    Johnson, Douglas B.
    Patrinely, J. Randall, Jr.
    Ye, Fei
    JAMA ONCOLOGY, 2021, 7 (10) : 1574 - 1575
  • [26] Onset, duration, and clinical impact of immune-related adverse events in Hodgkin lymphoma
    Higgins, Alexandra
    Richter, Michael D.
    Patel, Shruti
    McCullough, Kristen Beth
    Habermann, Thomas Matthew
    Ansell, Stephen M.
    Thompson, Carrie A.
    Bennani, Nabila Nora
    Thanarajasingam, Uma
    Thanarajasingam, Gita
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [27] Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
    Van Buren, Inga
    Madison, Cecelia
    Kohn, Aimee
    Berry, Elizabeth
    Kulkarni, Rajan P.
    Thompson, Reid F.
    JAMA NETWORK OPEN, 2023, 6 (10) : E2340695
  • [28] Immune-related adverse events after immune checkpoints inhibitors in 2019: An update
    Comont, T.
    Belliere, J.
    Sibaud, V.
    Alric, L.
    Meyer, N.
    Mazieres, J.
    Caron, P.
    Acket, B.
    Michot, J. -M.
    Beyne-Rauzy, O.
    Lambotte, O.
    REVUE DE MEDECINE INTERNE, 2020, 41 (01): : 37 - 45
  • [29] Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge
    Liu, Jie
    Yu, Jinming
    Meng, Xue
    JAMA ONCOLOGY, 2020, 6 (11) : 1813 - +
  • [30] Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
    Allouchery, Marion
    Lombard, Thomas
    Martin, Mickael
    Rouby, Franck
    Sassier, Marion
    Bertin, Celia
    Atzenhoffer, Marina
    Miremont-Salame, Ghada
    Perault-Pochat, Marie-Christine
    Puyade, Mathieu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
12345